Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
The Lancet. Oncology|July 6, 2023
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working GroupMeletios A Dimopoulos, Giampaolo Merlini, Frank Bridoux, et al.
Nature Genetics|August 20, 2025
Temporal genomic dynamics shape clinical trajectory in multiple myelomaFrancesco Maura, Marcella Kaddoura, Alexandra M Poos, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 14, 2023
Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma PatientsMichael A Thompson, Mario Boccadoro, Xavier Leleu, et al.
Blood Advances|May 5, 2026
Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONENizar J Bahlis, Thierry Facon, Jesús F San-Miguel, et al.
Nature Medicine|April 6, 2026
Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trialFrancesca Gay, Wilfried Roeloffzen, Meletios A Dimopoulos, et al.
Biorxiv : the Preprint Server for Biology|September 16, 2024
Temporal Genomic Dynamics Shape Clinical Trajectory in Multiple MyelomaFrancesco Maura, Marcella Kaddoura, Alexandra M Poos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2012
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trialPieter Sonneveld, Ingo G H Schmidt-Wolf, Bronno van der Holt, et al.
The Lancet. Haematology|February 1, 2024
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trialElias K Mai, Hartmut Goldschmid, Kaya Miah, et al.
The Lancet. Haematology|November 3, 2022
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trialHartmut Goldschmidt, Elias K Mai, Uta Bertsch, et al.
Nature Reviews. Clinical Oncology|July 7, 2025
EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myelomaMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.
Pageof 10